Adamis Pharmaceuticals Corporation (ADMP) financial statements (2020 and earlier)

Company profile

Business Address 11455 EL CAMINO REAL
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
3/31/2014
3/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:121917545 
Cash and cash equivalents121917445 
Other undisclosed cash, cash equivalents, and short-term investments   1   
Receivables (0)     
Inventory, net of allowances, customer advances and progress billings3321 
Inventory3321   
Prepaid expense 100000
Deferred costs      0
Other current assets 000000
Other undisclosed current assets4321   
Total current assets:1826217450
Noncurrent Assets
Finance lease, right-of-use asset0
Operating lease, right-of-use asset2
Property, plant and equipment12107500 
Intangible assets, net (including goodwill)19212326810
Goodwill8888   
Intangible assets, net (excluding goodwill)12131618810 
Deposits noncurrent assets00000  
Other noncurrent assets22    
Total noncurrent assets:35333031810 
TOTAL ASSETS:5358513812150
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7864113
Accounts payable3432012
Accrued liabilities2222001
Employee-related liabilities11100  
Deferred revenue1
Debt3324 01
Deferred compensation liability     1 
Derivative instruments and hedges, liabilities      0
Deferred revenue and credits00   
Other liabilities    1  
Other undisclosed current liabilities 1  000
Total current liabilities:111299335
Noncurrent Liabilities
Long-term debt and lease obligation2 33   
Long-term debt, excluding current maturities  33   
Finance lease, liability0
Operating lease, liability2
Liabilities, other than long-term debt 001   
Deferred tax liabilities, net001   
Other undisclosed noncurrent liabilities0      
Total noncurrent liabilities:2034   
Total liabilities:13121213335
Stockholders' equity
Stockholders' equity attributable to parent40474025912(4)
Preferred stock   00  
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital217200154114785834
Accumulated deficit(177)(153)(114)(88)(69)(46)(38)
Total stockholders' equity:40474025912(4)
TOTAL LIABILITIES AND EQUITY:5358513812150

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
3/31/2014
3/31/2013
Revenues2115136   
Revenue, net136   
Cost of revenue
(Cost of Goods and Services Sold)
(14)(10)(7)(5)   
Gross profit:6562   
Operating expenses(43)(45)(30)(27)(14)(5)(5)
Other undisclosed operating income     11
Operating loss:(37)(39)(25)(25)(14)(4)(3)
Nonoperating income (expense)00(1)10(4)(4)
Investment income, nonoperating0000 13
Interest and debt expense(0)(0)(0)(0) (9)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes   0   
Loss from continuing operations before equity method investments, income taxes:(37)(40)(26)(24)(14)(17)(9)
Other undisclosed income from continuing operations before income taxes000    
Loss from continuing operations before income taxes:(37)(39)(26)(24)(14)(17)(9)
Income tax benefit 005   
Other undisclosed income from continuing operations0    92
Loss from continuing operations:(36)(39)(26)(19)(14)(8)(7)
Loss from discontinued operations      (0)
Net loss:(36)(39)(26)(19)(14)(8)(7)
Other undisclosed net loss attributable to parent(0)      
Net loss attributable to parent:(36)(39)(26)(19)(14)(8)(7)
Preferred stock dividends and other adjustments   (1)   
Other undisclosed net income available to common stockholders, basic7878     
Net income (loss) available to common stockholders, basic:4239(26)(21)(14)(8)(7)
Dilutive securities, effect on basic earnings per share    (0)  
Other undisclosed net loss available to common stockholders, diluted     (1) 
Net income (loss) available to common stockholders, diluted:4239(26)(21)(14)(9)(7)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
3/31/2014
3/31/2013
Net loss:(36)(39)(26)(19)(14)(8)(7)
Comprehensive loss, net of tax, attributable to parent:(36)(39)(26)(19)(14)(8)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: